ERBB2 and breast cancer: The primary objective of this comparative clinical trial in patients with operable HER2+ breast cancer was to determine whether neoadjuvant treatment with PF-05280014, a potential trastuzumab biosimilar, was non-inferior to trastuzumab-EU, based on pharmacokinetic data.